HopeStage
Back to all studies
CompletedNCT03249376

Lumateperone or Placebo for Depressive Episodes in Bipolarity

About this title

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

Read the official source — NCT03249376

Researchers compared Lumateperone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Medication studyAges 18–75Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Lumateperone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Listed locations
Birmingham and 46 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: November 27, 2017
Recruitment status
Completed
Enrollment listed in the registry
381
Sponsor
Intra-Cellular Therapies, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Bulgaria, Colombia, ...
Age range
From 18 Years to 75 Years
Official registry ID
NCT03249376
Official title
Show the full official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) Conducted Globally

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham, United States · Sherman Oaks, United States · Miami, United States

45 more locations
  • Orange City, United States
  • Atlanta, United States
  • Decatur, United States
  • Chicago, United States
  • Joliet, United States
  • Shreveport, United States
  • St Louis, United States
  • Buffalo, United States
  • Charlotte, United States
  • The Woodlands, United States
  • Bothell, United States
  • Burgas, Bulgaria
  • Kardzhali, Bulgaria
  • Lovech, Bulgaria
  • Plovdiv, Bulgaria
  • Rousse, Bulgaria
  • Sofia, Bulgaria
  • Targovishte, Bulgaria
  • Tsarev Brod, Bulgaria
  • Varna, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Barranquilla, Colombia
  • Bello, Colombia
  • Pereira, Colombia
  • Moscow, Russia
  • Nizhny Novgorod, Russia
  • Omsk, Russia
  • Saint Petersburg, Russia
  • Samara, Russia
  • Saratov, Russia
  • Tomsk, Russia
  • Yekaterinburg, Russia
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Novi Sad, Serbia
  • Ivano-Frankivsk, Ukraine
  • Kharkiv, Ukraine
  • Kherson, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Poltava, Ukraine
  • Smila, Ukraine
  • Uzhhorod, Ukraine
  • Vinnytsia, Ukraine
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Lumateperone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Who is behind this study?

The study sponsor is Intra-Cellular Therapies, Inc.

Did this study involve medication?

Yes. The study involved medication, including Lumateperone.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies